148 related articles for article (PubMed ID: 14321143)
1. EFFECT OF FIBRIN AND FIBRINOGEN PROTEOLYSIS PRODUCTS ON CLOT PHYSICAL PROPERTIES.
HIRSH J; FLETCHER AP; SHERRY S
Am J Physiol; 1965 Aug; 209():415-24. PubMed ID: 14321143
[No Abstract] [Full Text] [Related]
2. [Interrelationship between contact coagulation, surface charge and roughness].
Chepurov AK; Mertsalova NN
Fiziol Zh SSSR Im I M Sechenova; 1978 Nov; 64(11):1559-67. PubMed ID: 153245
[TBL] [Abstract][Full Text] [Related]
3. Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation.
Barua RS; Sy F; Srikanth S; Huang G; Javed U; Buhari C; Margosan D; Ambrose JA
Arterioscler Thromb Vasc Biol; 2010 Jan; 30(1):75-9. PubMed ID: 19815816
[TBL] [Abstract][Full Text] [Related]
4. Additive roles of platelets and fibrinogen in whole-blood fibrin clot formation upon dilution as assessed by thromboelastometry.
Ninivaggi M; Feijge MA; Baaten CC; Kuiper GJ; Marcus MA; Ten Cate H; Lancé MD; Heemskerk JW; van der Meijden PE
Thromb Haemost; 2014 Mar; 111(3):447-57. PubMed ID: 24258426
[TBL] [Abstract][Full Text] [Related]
5. Changes in fibrinogen and fibrin induced by a peptide analog of fibrinogen gamma365-380.
Dempfle CE; Bindeballe N; Münchbach M; Blume C; Borggrefe M; Mosesson MW
J Thromb Haemost; 2007 Aug; 5(8):1707-14. PubMed ID: 17663740
[TBL] [Abstract][Full Text] [Related]
6. A serum-induced defect in fibrin formation.
Deykin D; Silversmith P; Ashford T
J Lab Clin Med; 1970 Nov; 76(5):761-74. PubMed ID: 4249037
[No Abstract] [Full Text] [Related]
7. STUDY OF THE ANTI-THROMBOTIC PROPERTIES OF DEXTRANS OF LARGE MOLECULAR WEIGHT.
BRYANT MF; BLOOM WL; BREWER SS
J Cardiovasc Surg (Torino); 1964; 5():48-52. PubMed ID: 14109832
[No Abstract] [Full Text] [Related]
8. AN ULTRASTRUCTURAL INVESTIGATION OF THE FIBRIN CLOT UTILIZING FERRITIN-LABELLED ANTI-HUMAN FIBRINOGEN ANTIBODY.
WHITE JG; KRIVIT W; VERNIER R
Blood; 1964 Oct; 24():443-50. PubMed ID: 14220786
[No Abstract] [Full Text] [Related]
9. Thromboelastographic phenotypes of fibrinogen and its variants: clinical and non-clinical implications.
Galanakis DK; Neerman-Arbez M; Brennan S; Rafailovich M; Hyder L; Travlou O; Papadakis E; Manco-Johnson MJ; Henschen A; Scharrer I
Thromb Res; 2014 Jun; 133(6):1115-23. PubMed ID: 24679643
[TBL] [Abstract][Full Text] [Related]
10. The influence of poly-N-[(2,2-dimethyl-1,3-dioxolane)methyl]acrylamide on fibrin polymerization, cross-linking and clot structure.
Lai BF; Zou Y; Brooks DE; Kizhakkedathu JN
Biomaterials; 2010 Aug; 31(22):5749-58. PubMed ID: 20435346
[TBL] [Abstract][Full Text] [Related]
11. An inherited qualitative abnormality in plasma fibrinogen: fibrinogen Cleveland.
Forman WB; Ratnoff OD; Boyer MH
J Lab Clin Med; 1968 Sep; 72(3):455-72. PubMed ID: 5674077
[No Abstract] [Full Text] [Related]
12. [Studies on fibrinolysis in equivalents of the Sanarelli-Shwartzman phenomenon in obstetrics. Immunochemical demonstration of derivatives of fibrin(ogen)].
Steichele DF; Herschlein HJ
Thromb Diath Haemorrh; 1967 Dec; 18(3-4):462-74. PubMed ID: 5590239
[No Abstract] [Full Text] [Related]
13. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products.
FLETCHER AP; ALKJAERSIG N; SHERRY S
J Clin Invest; 1962 Apr; 41(4):896-916. PubMed ID: 13893560
[No Abstract] [Full Text] [Related]
14. THE PLATELET-FIBRIN RELATIONSHIP IN HUMAN BLOOD CLOTS: AN ULTRASTRUCTURAL STUDY UTILIZING FERRITIN-CONJUGATED ANTI-HUMAN FIBRINOGEN ANTIBODY.
WHITE JG; KRIVIT W; VERNIER RL
Blood; 1965 Feb; 25():241-57. PubMed ID: 14267700
[No Abstract] [Full Text] [Related]
15. Formation of highly ordered polymers from fibrinogen and fibrin degradation products.
Niewiarowski S; Stewart GJ; Marder VJ
Biochim Biophys Acta; 1970 Nov; 221(2):326-41. PubMed ID: 4249928
[No Abstract] [Full Text] [Related]
16. [A new case of dysfibrinogenemia].
Krause W; Heene D; Lasch HG
Klin Wochenschr; 1971 Jul; 49(14):806-8. PubMed ID: 5563018
[No Abstract] [Full Text] [Related]
17. Quantitation of the coagulation inhibition in vivo due to breakdown products of fibrin.
Mitchell PS; Beller FK
Thromb Diath Haemorrh; 1970 Jun; 23(3):477-85. PubMed ID: 4989113
[No Abstract] [Full Text] [Related]
18. The influence of fibrin polymerization and platelet-mediated contractile forces on citrated whole blood thromboelastography profile.
Chakroun T; Gerotziafas GT; Seghatchian J; Samama MM; Hatmi M; Elalamy I
Thromb Haemost; 2006 May; 95(5):822-8. PubMed ID: 16676074
[TBL] [Abstract][Full Text] [Related]
19. Biophysics. Enigmas of blood clot elasticity.
Weisel JW
Science; 2008 Apr; 320(5875):456-7. PubMed ID: 18436761
[No Abstract] [Full Text] [Related]
20. [Immunoelectrophoretic study of fibrinogen and of degradation products of fibrinogen and fibrin].
Karpinskaia VM
Probl Gematol Pereliv Krovi; 1968 Jan; 13(1):53-6. PubMed ID: 5736826
[No Abstract] [Full Text] [Related]
[Next] [New Search]
